AB0304 Serum levels of sclerostin and DICKKOPF-1, and their correlation with bone mineral density and bone markers in rheumatoid arthritis

AbstractRheumatoid arthritis (RA) is a chronic inflammatory disease characterized by synovial inflammation and destruction of joint cartilage and bone. Different cytokines play important role in the processes that cause articular destruction and extra-articular manifestations in RA. The contribution of cytokines representing the Th1 (INF-γ), Th2 (IL-4) and IL-17A to the pathogenesis of early RA and bone mineral density (BMD) loss in still poorly understood. Serum samples of 38 early RA patients were evaluated for erythrocyte sedimentation rate (ESR), rheumatoid factor (RF), C-reactive protein (CRP), anti-cyclic citrullinated peptide antibodies (anti-CCP) and for the tested cytokines (IL-17A, IL-4 and INF-γ). BMD was evaluated by dualenergyX-ray absorptiometry (DXA). Disease activity score (DAS28) calculation was assessed for all patients. Control serum samples were obtained from 34 healthy volunteers. The levels of tested cytokines were significantly higher (IL-17A, p<0.001; INF-γ, P<0.001; IL-4, P<0.01) in patients with early RA, compared to the healthy controls. In early RA patients, strong correlation of serum IL-17A was found with DAS28, ESR and CRP. Also, a significant negative correlation was found between serum INF-γ levels and the DAS28 score. Significantly positive correlation of BMD values and CRP, DAS28 IL-17A were also demonstrated. DXA analysis revealed that the most common site for osteoporosis was the lumbar spine followed by the femoral neck. BMD values significantly correlated with CRP, DAS28 score and IL-17A serum levels. The mean serum IL-17A levels, in patients with early RA, corresponded with disease activity, severity and BMD loss, indicating the potential usefulness of serum IL-17A in defining the disease activity and bone remodeling.

Download Full-text

Effect of aromatase inhibition on serum levels of sclerostin and dickkopf-1, bone turnover markers and bone mineral density in women with breast cancer

Journal of Cancer Research and Clinical Oncology ◽

10.1007/s00432-014-1726-z ◽

2014 ◽

Vol 140 (10) ◽

pp. 1671-1680 ◽

Cited By ~ 22

Author(s):

Ioannis Kyvernitakis ◽

Tilman D. Rachner ◽

Anja Urbschat ◽

Olaf Hars ◽

Lorenz C. Hofbauer ◽

...

Keyword(s):

Breast Cancer ◽

Bone Mineral Density ◽

Bone Turnover ◽

Bone Mineral ◽

Bone Turnover Markers ◽

Serum Levels ◽

Mineral Density ◽

Aromatase Inhibition ◽

Turnover Markers ◽

Dickkopf 1

Download Full-text

Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NF B ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis

Annals of the Rheumatic Diseases ◽

10.1136/ard.2005.044198 ◽

2006 ◽

Vol 65 (11) ◽

pp. 1495-1499 ◽

Cited By ~ 148

Author(s):

M Vis ◽

E A Havaardsholm ◽

G Haugeberg ◽

T Uhlig ◽

A E Voskuyl ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Bone Mineral Density ◽

Bone Metabolism ◽

Bone Mineral ◽

Serum Levels ◽

Mineral Density ◽

Receptor Activator

Download Full-text

Change in bone mineral density with high-dose prednisone in patients with rheumatoid arthritis

Bone Abstracts ◽

10.1530/boneabs.5.p463 ◽

2016 ◽

Author(s):

Linda Rasch ◽

Tuyl Lilian van ◽

Martijn Kremer ◽

Irene Bultink ◽

Maarten Boers ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Bone Mineral Density ◽

Bone Mineral ◽

High Dose ◽

Mineral Density ◽

Dose Prednisone

Download Full-text

The influence of the 24-month treatment with anti-CD20 antibodies (rituximab) on bone mineral density in patients with rheumatoid arthritis

Bone Abstracts ◽

10.1530/boneabs.3.pp10 ◽

2014 ◽

Author(s):

Polina Dydykina ◽

Irina Dydykina ◽

Anna Devyataikina ◽

Galina Lukina ◽

Alexandr Smirnov ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Bone Mineral Density ◽

Bone Mineral ◽

Mineral Density ◽

Anti Cd20 ◽

Cd20 Antibodies

Download Full-text

FRI0077 Factors Predicting Change in Bone Mineral Density in Patients with Rheumatoid Arthritis: the Tomorrow Study: Table 1

Annals of the Rheumatic Diseases ◽

10.1136/annrheumdis-2014-eular.1729 ◽

2014 ◽

Vol 73 (Suppl 2) ◽

pp. 409.1-409

Author(s):

M. Tada ◽

T. Koike ◽

K. Inui ◽

Y. Sugioka ◽

K. Mamoto ◽

...

Keyword(s):

Rheumatoid Arthritis ◽

Bone Mineral Density ◽

Bone Mineral ◽

Mineral Density

Download Full-text

P129 Predictors of low bone mineral density in rheumatoid arthritis

Rheumatology ◽

10.1093/rheumatology/keab247.124 ◽

2021 ◽

Vol 60 (Supplement_1) ◽

Author(s):

Malika A Swar ◽

Marwan Bukhari

Keyword(s):

Rheumatoid Arthritis ◽

Risk Factors ◽

Bone Mineral Density ◽

Family History ◽

Bone Loss ◽

Femoral Neck ◽

Bone Mineral ◽

Fragility Fracture ◽

Mineral Density ◽

History Of

Abstract Background/Aims Osteoporosis (OP) is an extra-articular manifestation of rheumatoid arthritis (RA) that leads to increased fracture susceptibility due to a variety of reasons including immobility and cytokine driven bone loss. Bone loss in other populations has well documented risk factors. It is unknown whether bone loss in RA predominantly affects the femoral neck or the spine. This study aimed to identify independent predictors of low bone mineral density (BMD) in patients RA at the lumbar spine and the femoral neck. Methods This was a retrospective observational cohort study using patients with Rheumatoid arthritis attending for a regional dual X-ray absorptiometry (DEXA) scan at the Royal Lancaster Infirmary between 2004 and 2014. BMD in L1-L4 in the spine and in the femoral neck were recorded. The risk factors investigated were steroid use, family history of osteoporosis, smoking, alcohol abuse, BMI, gender, previous fragility fracture, number of FRAX(tm) risk factors and age. Univariate and Multivariate regression analysis models were fitted to explore bone loss at these sites using BMD in g/cm2 as a dependant variable. . Results 1,527 patients were included in the analysis, 1,207 (79%) were female. Mean age was 64.34 years (SD11.6). mean BMI was 27.32kg/cm2 (SD 5.570) 858 (56.2%) had some steroid exposure . 169(11.1%) had family history of osteoporosis. fragility fracture history found in 406 (26.6%). 621 (40.7%) were current or ex smokers . There was a median of 3 OP risk factors (IQR 1,3) The performance of the models is shown in table one below. Different risk factors appeared to influence the BMD at different sites and the cumulative risk factors influenced BMD in the spine. None of the traditional risk factors predicted poor bone loss well in this cohort. P129 Table 1:result of the regression modelsCharacteristicB femoral neck95% CIpB spine95%CIpAge at scan-0.004-0.005,-0.003<0.01-0.0005-0.002,0.00050.292Sex-0.094-0.113,-0.075<0.01-0.101-0.129,-0.072<0.01BMI (mg/m2)0.0080.008,0.0101<0.010.01130.019,0.013<0.01Fragility fracture-0.024-0.055,0.0060.12-0.0138-0.060,0.0320.559Smoking0.007-0.022,0.0350.650.0286-0.015,0.0720.20Alcohol0.011-0.033,0.0 5560.620.0544-0.013,0.1120.11Family history of OP0.012-0.021,0.0450.470.0158-0.034,0.0650.53Number of risk factors-0.015-0.039,0.0080.21-0.039-0.075,-0.0030.03steroids0.004-0.023,0.0320.030.027-0.015,0.0690.21 Conclusion This study has shown that predictors of low BMD in the spine and hip are different and less influential than expected in this cohort with RA . As the FRAX(tm) tool only uses the femoral neck, this might underestimate the fracture risk in this population. Further work looking at individual areas is ongoing. Disclosure M.A. Swar: None. M. Bukhari: None.

Download Full-text